The Relationship Between TIMI Flow and MAPH Score in Patients Undergoing Primary Percutaneous Coronary Intervention for STEMI
Yükleniyor...
Dosyalar
Tarih
2023
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
International Heart Journal Association
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
The MAPH (mean platelet volume, age, total protein and hematocrit) score is a newly developed simple scoring system for patients with STEMI that has been associated with satisfactory predictive values to determine thrombus burden in STEMI patients. Therefore, the aim of our study was to determine the relationship between the MAPH risk score and TIMI flow in patients with STEMI. The study included 260 patients who underwent primary percutaneous coronary intervention between December 2019 to July 2022, and had TIMI 0 flow in the responsible coronary artery due to STEMI. According to the TIMI flow score after stent implantation, the patients were classified into either the no-reflow group (n = 59) or the normal flow group (n = 201). In order to calculate the MAPH score, ROC analysis was performed to find the cutoff point for each component of the MAPH score. MAPH scores were calculated (MPV + Age + Protein + Hematocrit) for both groups. Our study was a retrospective, observational study. In the multivariable regression analysis, the MAPH score (OR: 0.567; 95%CI: 0.330-0.973, P = 0.04) and glycoprotein IIb/IIIa inhibitors (OR: 0.249; 95%CI: 0.129-0.483, P < 0.001) were parameters found to be independent predictors of TIMI flow. An MAPH score value > 2.5 predicted the presence of low TIMI coronary flow in patients with STEMI, with 78% specificity and 45% sensitivity (ROC area under curve: 0.691, 95% CI: 0.617-0.766, P < 0.001). The MAPH risk score is simple, inexpensive, and quick to calculate. A high MAPH score may be an indi-cator of coronary no-reflow in patients with STEMI. © 2023, International Heart Journal Association. All rights reserved.
Açıklama
Anahtar Kelimeler
Myocardial infarction; No-reflow; Predictors; TIMI flow grade, acetylsalicylic acid; cholesterol; clopidogrel; glycoprotein P inhibitor; low density lipoprotein cholesterol; prasugrel; protein; ticagrelor; tirofiban; triacylglycerol; adult; albumin blood level; Article; blood cell count; blood clotting time; chronic kidney failure; controlled study; coronary angiography; coronary artery; coronary artery pressure; creatinine blood level; demographics; diabetes mellitus; diagnostic test accuracy study; fasting blood glucose level; female; fractional flow reserve; glomerulus filtration rate; glucose blood level; health insurance; heart infarction; hematocrit; high density lipoprotein cholesterol level; human; hyperlipidemia; hypertension; implantation; intravascular ultrasound; kidney function test; left anterior descending coronary artery; leukocyte count; lipid blood level; lymphocyte count; major clinical study; male; mean platelet volume; middle aged; neutrophil count; observational study; percutaneous coronary intervention; platelet count; receiver operating characteristic; retrospective study; scoring system; sensitivity and specificity; smoking; ST segment elevation myocardial infarction; thrombolysis in myocardial infarction score; thrombus; thrombus aspiration; urea blood level
